Every pregnancy deserves Panorama™
Pregnancy can be exciting for families, and also bring concerns about medical decisions or the challenges of parenting. Prenatal screening offers genetic insights early in pregnancy about the health of a pregnant person and their growing baby. Panorama™ noninvasive prenatal test is trusted by 1 in 3 OBGYNs in the US to deliver these insights for more than 1 million families each year1.
#1 NIPT for a reason
The Panorama™ difference
- The only SNP-based NIPT, designed to inform decisions during pivotal moments of pregnancy care.
- A differentiated, highly-accurate screening approach evaluates SNPs – the 1% of our DNA that makes us different from one another – to screen for common trisomies, aneuploidies and microdeletions.
- A sequencing platform of >13K SNPs enables Panorama to deliver a curated prenatal cfDNA screening test that accounts for all ethnicities and population variability.
Validated with clinical rigor
SMART, the largest prospective NIPT study, evaluated the performance of SNP-based NIPT in a real-world population. All results included in the analysis were validated with genetic confirmation.4-6
Is Panorama™ right for you?
We’re here to help you find out
1Internal data on file as of June 2023.
2Natera and non-Natera published peer-reviewed publications.
3Goldring et al. Obstet Gynecol. 2023 Apr 1;141(4):791-800.
4Dar et al. Am J Obstet Gynecol. Published online January 24, 2022. doi:10.1016/j.ajog.2022.01.019.
5Dar et al. Am J Obstet Gynecol. Published online January 13, 2022. doi:10.1016/j.ajog.2022.01.002.
6Norton et al. Perinatal and genetic outcomes associated with no call cfDNA results in 18,497 pregnancies. Society of Maternal-Fetal Medicine, SMFM. Virtual Meeting. Oral Presentation. Jan 25-30, 2021.
7ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct;136(4):859-867.
* CA residents: If your clinician ordered screening through the California Prenatal Screening program using Natera's Vasistera™ NIPT, Panorama™ will only screen for supplemental conditions. If this is the case, trisomies 21, 18 and 13, and fetal sex (optional) will be screened using Vasistera™ NIPT and will be reported separately.
** Not available for egg-donor or gestational carrier pregnancies or in cases of dizygotic (nonidentical) twins. Triploidy and microdeletions except for 22q11.2 deletions are not available for monozygotic (identical) twins.
† This test has been validated on full region deletions of Prader-Willi syndrome/Angelman syndrome (PWS/AS) only and might be unable to detect smaller deletions. It has not been validated for other molecular mechanisms which could cause PWS/AS such as uniparental disomy (UPD) or methylation.